Promene nivoa CD4+CD25high T ćelija i TGFβ1 u različitim stadijumima adultnog Tipa 1 dijabetesa

Stages in T1D: differences in CD25high T cells and TGFβ1

  • Tanja Miličić Medicinski fakultet UB, Klinika za endokrinologiju, dijabetes i bolesti metabolizma UKCS
  • Aleksandra Jotić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Ivanka Marković Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Dušan Popadić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Katarina Lalić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Veljko Uskoković Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Ljiljana Lukić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Marija Maćešić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Jelena Stanarčić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Milica Stoiljković Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Mina Milovančević Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Djurdja Rafailović Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Aleksandra Božović Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Nina Radisavljević Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
  • Nebojša Lalić Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetski Klinički Centar Srbije, Medicinski fakultet Univerzitet u Beogradu
DOI: https://doi.org/10.5937/jomb0-49868
Ključne reči: CD4 CD25high T ćelije, TGFβ, prvi rođaci pacijenata sa tipom 1 dijabetesa, tip 1 dijabetesa

Sažetak


Prethodne studije su pokazale važnu ulogu poremećaja nivoa T ćelijskih subsetova u različitim stadijumima razvoja tipa 1 dijabetesa (T1D), dok su podaci vezani za CD25high T ćelije i transformišući faktor rasta β1 (transforming growth factor-TGFβ1), koji parcijalno reflektuju T regulatorni odgovor, i dalje kontroverzni. Analizirali smo nivo (a) CD25high T ćelija (b) TGFβ1 kod 17 prvih rođaka pacijenata sa T1D u stadijumu 1 (first-degree relatives of patients with T1D - FDRs1), sa povećanim rizikom za T1D, (GADA+, IA-2+); 34 FDRs u stadijumu 0 (FDRs0) (GADA-, IA-2-); 24 pacijenta sa novootkrivenim T1D u insulin-zavisnom stanju (insulin requiring state-IRS); 10 pacijenata u kliničkoj remisiji (CR); 18 zdravih kontrola (CTR). Nivo CD4+CD25high T ćelija je analiziran metodom dvobojne imunofluorescencije i protočne citometrije, TGFβ1 ELISA, GADA i IA-2 RIA metodom. Nivo CD25high T ćelija u FDRs1 je niži u poređenju sa kontrolama, FDRs0, IRS i CR (p<0.001). Nivo CD25high T ćelija od 1.19%, sa verovatnoćom 0.667, prediktuje povećan rizik za T1D. Nivo TGFβ1 u FDRs1, FDRs0, i oba stanja u T1D, IRS i CR, je niži u poređenju sa kontrolama (p<0.001). U celini, pokazali smo da stadijum 1, povišen rizik za ispoljavanje T1D, karakterišu smanjenja u nivou CD25high T ćelija i TGFβ1, delimično reflektujući oštećen imunoregulatorni odgovor, što bi mogao biti marker rizika za T1D. FDRs sa i bez rizika za T1D i pacijenti sa T1D bez obzira na stanje, su imali snižen TGFβ1, što sugeriše udruženost TGFβ1 sa familijarnim rizikom i kliničkom manifestacijom T1D. Takođe, klinički tok T1D bi mogao biti moduliran na nivou TGFβ1.

Reference

1. Siljander H. T., Veijola R., Reunanen A., Virtanen S. M., Akerblom H. K., and Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia, 2007; 50 (11): 2272–2275.
2. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010 Apr 23;32(4):468-78. doi: 10.1016/j.immuni.2010.03.018. PMID: 20412757; PMCID: PMC2861716.
3. Insel RA, Dunne JL, Atkinson MA, et al.. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964–1974
4. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109:131–140.
5. Michalek J., Vrabelova Z., Hrotekova Z., Kyr M., Pejchlova M., Kolouskova S.,et al. Immune Regulatory T Cells in Siblings of Children Suffering from Type 1 Diabetes Mellitus Scandinavian Journal of Immunology 2006; 64: 531–535.
6. Vrabelova Z., Hrotekova Z., Hladikova Z., Bohmova K., Stechova K., Michalek J. CD 127- and FoxP3+ Expression on CD25+CD4+ T Regulatory Cells upon Specific Diabetogeneic Stimulation in High-risk Relatives of Type 1 Diabetes Mellitus Patients Scand J Immunol. 2008 Apr;67(4):404-10.
7. Oling V, Marttila J, Knip M, Simell O, Ilonen O. Circulating CD4+CD25+high regulatory T cells and natural kuller T cells in children with newly diagnosed type 1 diabetes or with diabetes asspciated autoantibodies, Ann N Y Acad Sci 2007 Jun; 1107:363-72.
8. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz M, Atkinson MA. Functional Defects and the Influence of Age on the Frequency of CD4+CD25+ T-Cells in Type 1 Diabetes. Diabetes 2005; 54:1407-1414.
9. Mason GM, Lowe K, Melchiotti R, Ellis R, de Rinaldis E, Peakman M, et al. Phenotypic complexity of the human regulatory t cell compartment revealed by mass cytometry. J Immunol. 2015; 195:2030–7. doi: 10.4049/jimmunol.1500703
10. Hull, C.M., Peakman, M. & Tree, T.I.M. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it?. Diabetologia 2017; 60: 1839–1850. https://doi.org/10.1007/s00125-017-4377-1
11. Baecher-Allan C., Brown J. A., Freeman G. J., and Hafler D. A. “CD4+CD25high regulatory cells in human peripheral blood,” Journal of Immunology, 2001;167(3): 1245–1253.
12. Busse D, de la Rosa M, Hobiger K et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A. 2010;107:3058–3063.
13. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004; 16:89 –98.
14. Wan YY, Flavell RA. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev. 2007 Dec;220:199-213. doi: 10.1111/j.1600-065X.2007.00565.x. PMID: 17979848; PMCID: PMC2614905.
15. Milicic T, Jotic A, Markovic I, Lalic K, Jeremic V, Lukic L, et. al. High Risk First Degree Relatives of Type 1 Diabetics: An Association with Increases in CXCR3(+) T Memory Cells Reflecting an Enhanced Activity of Th1 Autoimmune Response. Int J Endocrinol. 2014;2014:589360. doi: 10.1155/2014/589360. Epub 2014 Mar 23. PMID: 24778649; PMCID: PMC3979071.
16. Fonolleda M, Murillo M, Vázquez F, Bel J, Vives-Pi M. Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers. Horm Res Paediatr. 2017;88(5):307-315. doi: 10.1159/000479030. Epub 2017 Aug 3. PMID: 28772271.
17. Nicoletti F, Di Marco R, Patti F, Reggio E, Nicoletti A, Zaccone P, et al.. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). Clin Exp Immunol. 1998 Jul;113(1):96-9. doi: 10.1046/j.1365-2249.1998.00604.x. PMID: 9697990; PMCID: PMC1905006
18. Viisanen T, Gazali AM, Ihantola E-L, Ekman I, Näntö-Salonen K, Veijola R, et al. FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children. Front. Immunol. 2019;10:19. doi: 10.3389/fimmu.2019.00019
19. Tree TI, Roep BO, Peakman M. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann N Y Acad Sci 2006;1079 : 9–18.
20. Putnam, A.L., Vendrame F., Dotta F. Gottlieb P.A. CD4+CD25high regulatory T cells in human autoimmune diabetes. J. Autoimmun. 2005; 24: 55–62.
21. NCT 00336674. Trial of intranasal insulin in children and young adults at risk of Type 1 diabetes (INIT II). Available at http://www.ClinicalTrials.gov
22. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701–1711
23. Fathy M, El Araby I, El Guindy N, and Anwar G. CD4 CD25 T Cells in Children with Recent Onset Type 1 Diabetes. Med. J. Cairo Univ, 2021; 89(3), June: 1079-1087
24. Łuczyński W, Wawrusiewicz-Kurylonek N, Stasiak-Barmuta A, Urban R, Iłendo E, Urban M, et al. Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes. Acta biochimica polonica 2009; (56):2/, –000
25. Zhang Y, Zhang J, Shi Y, Shen M, Lv H, Chen S, et al. Differences in Maturation Status and Immune Phenotypes of Circulating Helios+ and Helios− Tregs and Their Disrupted Correlations With Monocyte Subsets in Autoantibody Positive T1D Individuals. Front. Immunol. 2021; 12:628504. doi: 10.3389/fimmu.2021.628504
26. Tiittanen M, Huupponen JT, Knip M and Vaarala O. Insulin Treatment in Patients With Type 1 Diabetes Induces Upregulation of Regulatory T-Cell Markers in Peripheral Blood Mononuclear Cells Stimulated With Insulin In Vitro. Diabetes 2006; 55:3446–3454.
27. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005;54:92–9.
28. Starosz A, Jamiołkowska Sztabkowska M, Głowinska Olszewska B, Moniuszko M, Bossowski A and Grubczak K. Immunological balance between Treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children. Front. Immunol. 2022;13:958430. doi: 10.3389/fimmu.2022.958430
29. Narsale A. Lam B., Moya R., Lu T., Mandelli A., Gotuzzo I. et al. CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes. JCI Insight. 2021;6(2):e136114. https://doi.org/10.1172/jci.insight.136114
30. Stechova K., Bohmova K., Vrabelova Z., Sepa A., Stadlerova G., Zacharovova K., et al. High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes Diabetes Metab Res Rev 2007; 23: 462–471.
31. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol 2001; 53:510–13.
32. Faresj¨o M, Vaarala O, Thuswaldner S, Ilonen J, Hinkkanen A, Ludvigsson J. Diminished IFN-γ response to diabetes-associated autoantigens in children at diagnosis and during follow up of type 1 diabetes Diabetes Metab Res Rev 2006; 22: 462–470.
33. Tian B, Hao J, Zhang Y, Tian L, Yi H, O’Brien TD, et al. Upregulating CD4+CD25+FoxP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 2009; 87: 198–206.
Objavljeno
2024/07/04
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2024 Tanja Miličić, Aleksandra Jotic, Ivanka Markovic, Dusan Popadic, Katarina Lalic, Veljko Uskokovic, Ljiljana Lukic, Marija Macesic, Jelena Stanarcic, Milica Stoiljkovic, Mina Milovancevic, Djurdja Rafailovic, Aleksandra Bozovic, Nina Radisavljevic, Nebojsa Lalic

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.